Relief Therapeutics Holding SA

Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023

Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting

Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA™ 

Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa

Relief Therapeutics Provides an Update on its Financing Strategy

Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphoma